Chemical Inhibitors of CREB-mediated Gene Transcription
Chemical Inhibitors of CREB-mediated Gene Transcription
批准号:
8512736
负责人:
Xiangshu Xiao
金额:
$30.9万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2015-07-31
关键词:
Acute leukemiaAddressAmino AcidsAnilineAntineoplastic AgentsApoptosisBindingBinding ProteinsBinding SitesBiochemicalBiologicalBiological AssayBiological ProcessCREB-binding proteinCREB1 geneCancer Cell GrowthCancer PatientCancer cell lineCell DeathCell LineCell ProliferationCell SurvivalCellsChemicalsCyclic AMP-Responsive DNA-Binding ProteinDevelopmentDominant-Negative MutationEvaluationGene TargetingGenetic TranscriptionGoalsHumanIn VitroLabelLeadLigand BindingLigandsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMapsMediatingModelingMolecularMonitorNaphtholsNeoplasm MetastasisNormal CellOligonucleotidesP-GlycoproteinPhenotypePhosphorylationPhosphotransferasesProtein BindingRegulationRelapseRenilla LuciferasesReporter GenesResearchSeriesSolubilitySpecificityStructure-Activity RelationshipTherapeuticTimeToxic effectTranscriptional Activationanaloganticancer activityanticancer treatmentaqueousbasecancer cellcancer cell differentiationcancer therapycell growthcytotoxicitydesignefflux pumphuman CREBBP proteinin vitro activityin vivoinhibitor/antagonistleukemiamalignant breast neoplasmmelanomamutantneoplastic cellneuron developmentnoveloverexpressionprostate cancer cellpublic health relevanceresearch studysmall moleculestructural biologytooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of the proposed research is to develop small molecule inhibitors of CREB (cAMP-response element binding protein)-mediated gene transcription as potential anticancer agents. Recently, accumulating evidence has revealed that CREB participates in the regulation of immortalization, transformation and metastasis of cancer cells. In some cancer patients (e.g. acute leukemia, prostate cancer and breast cancer), expression of CREB correlated with cancer phenotypes including cancer cell differentiation, metastasis, time to relapse and survival. This suggests that inhibiting the transcription activity of CREB could be a promising strategy for anticancer treatment. Consistent with this hypothesis, expression of a dominant-negative CREB mutant in melanoma and lung cancer cell lines or down-regulating the expression of CREB in leukemia cell lines reduced the transforming phenotypes of the cancer cells. Moreover, delivery of a CRE decoy oligonucleotide into human breast cancer or prostate cancer cells led to significant inhibition of tumor cell growth both in vitro and in vivo while similar experiments in normal cells showed no toxicity. These results indicate that pharmacologically inhibiting CREB activity could be an excellent strategy for cancer treatment. However, small molecule inhibitors of CREB-mediated have not been developed for evaluation of anticancer activity. We recently developed a novel assay to specifically look at CREB-CBP interaction and discovered naphthol AS-E as a small molecule inhibitor of CREB-CBP interaction both in vitro and in cells. Moreover, we found that this compound was able to inhibit cancer cell growth by inducing apoptosis in a number of different cancer cells irrespective of their p53 status. Based on these promising preliminary results, we propose to further evaluate its therapeutic potential and optimize its anticancer activity. The following aims will be addressed: 1) To define the structure-activity relationships (SAR) of naphthol AS-E as an anticancer agent and inhibitor of CREB-CBP interaction by designing and synthesizing analogs with different substitutions on the appendant phenyl ring; 2) To develop a novel series of naphthol AS-E derivatives with enhanced potency and aqueous solubility as probes for structural studies; 3) To investigate the hypothesis that CREB-mediated gene transcription is required for anticancer activity displayed by naphthol AS-E and its derivatives. Development of small molecule inhibitors CREB-mediated gene transcription will not only lead to potential therapeutics for cancer, but also provide a powerful tool to manipulate CREB's activity in vitro and in vivo to further dissect its biological functions.
PUBLIC HEALTH RELEVANCE: The proposed research is to develop chemical inhibitors of CREB-mediated gene transcription. These inhibitors are expected to be potential candidates as anticancer agents for a variety of cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemical Modulators of Nuclear Lamins
-
批准号:10062606
-
项目类别:
-
资助金额:$5.26万
-
财政年份:2020
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Modulators of Nuclear Lamins
-
批准号:10411359
-
项目类别:
-
资助金额:$11.4万
-
财政年份:2017
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Modulators of Nuclear Lamins
-
批准号:9533512
-
项目类别:
-
资助金额:$35.23万
-
财政年份:2017
-
负责人:Xiangshu Xiao
-
依托单位:
Synergistic Inhibitors of CREB-mediated Gene Transcription
-
批准号:10464627
-
项目类别:
-
资助金额:$32.01万
-
财政年份:2017
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Modulators of Nuclear Lamins
-
批准号:10219173
-
项目类别:
-
资助金额:$35.23万
-
财政年份:2017
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Modulators of Nuclear Lamins
-
批准号:10671949
-
项目类别:
-
资助金额:$12.06万
-
财政年份:2017
-
负责人:Xiangshu Xiao
-
依托单位:
Targeting EWS-ATF1 in CCSST
-
批准号:9527099
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2017
-
负责人:Xiangshu Xiao
-
依托单位:
Targeting EWS-ATF1 in CCSST
-
批准号:9372101
-
项目类别:
-
资助金额:$20.1万
-
财政年份:2017
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Inhibitors of CREB-mediated Gene Transcription
-
批准号:8712508
-
项目类别:
-
资助金额:$32.02万
-
财政年份:2010
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Inhibitors of CREB-mediated Gene Transcription
-
批准号:7993339
-
项目类别:
-
资助金额:$32.62万
-
财政年份:2010
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Inhibitors of CREB-mediated Gene Transcription
-
批准号:8306277
-
项目类别:
-
资助金额:$32.02万
-
财政年份:2010
-
负责人:Xiangshu Xiao
-
依托单位:
Chemical Inhibitors of CREB-mediated Gene Transcription
-
批准号:8136729
-
项目类别:
-
资助金额:$32.02万
-
财政年份:2010
-
负责人:Xiangshu Xiao
-
依托单位:
海外基金